Comparative Pharmacology
Head-to-head clinical analysis: SULPHRIN versus TERFONYL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SULPHRIN versus TERFONYL.
SULPHRIN vs TERFONYL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulindac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis. Its active sulfide metabolite is responsible for therapeutic effects.
TERFONYL is a sulfonamide antibiotic that inhibits bacterial dihydropteroate synthase, thereby blocking folate synthesis and bacterial DNA replication.
1-2 tablets (500-1000 mg paracetamol, 65-130 mg caffeine) orally every 4-6 hours as needed, not exceeding 8 tablets (4000 mg paracetamol) per day for adults.
2 g intravenously every 12 hours over 24 hours for susceptible infections.
None Documented
None Documented
2-3 hours; clinically, hepatic impairment may prolong to 5-10 hours requiring dose adjustment
Terminal elimination half-life is 2.5-4 hours in adults with normal renal function; prolonged to 12-24 hours in severe renal impairment (CrCl < 30 mL/min).
Renal: 85-90% as glucuronide and sulfate conjugates, 5-10% unchanged; biliary/fecal: <5%
Renal excretion accounts for 70-90% of elimination as unchanged drug via glomerular filtration and tubular secretion; biliary/fecal excretion constitutes 10-30%.
Category C
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic